Shannon Saccocia, CIO, Boston Private Spdr S&P Biotech Etf XBI-N DON'T BUY Jul 03, 2024

The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

She's very bullish healthcare. Buy it at $83. She's selling the $90 September calls, collecting $3.25.

XBI has been in the $80-90 range. Has strong free cash flow. A good way to diversify away from tech. You can sell calls against it.

Bought it last year, and just sold it. This stock has broken down.

Healthcare has been an ignored sector, but is enjoying some momentum and will do well in second-half 2024. McKesson, Merck and Amgen, all holdings in this ETF, are doing well and even making new highs. Also, biotech does well when rates come down.